Skip to main content

Adult Peak Pruritus NRS Efficacy Results

In the treatment of adults with uncontrolled moderate-to-severe atopic dermatitis

Rapid itch relief after the first dose (as measured at Week 2)
sustained at 1 year1,2

Significant itch results in 3 pivotal trials1,3

CHRONOS 18+ YEARS
Concomitant therapy with TCS
≥4-POINT REDUCTION IN PEAK
PRURITUS NRS
(secondary endpoint)2,4,a-c
  • At Week 16 in CHRONOS, 59% of adults treated with DUPIXENT + TCS (n=102) achieved a significant itch
    reduction     vs 20% with placebo + TCS (n=299; secondary endpoint; P<0.0001)1,2

Significant itch reduction was also demonstrated with DUPIXENT in monotherapy trials (secondary endpoint)1,3

41%

of adults treated with DUPIXENT (n=213) achieved ≥4-point reduction in Peak
Pruritus NRS vs 12% with placebo at Week 16 in SOLO 1 (n=212; P<0.001)

36%

of adults treated with DUPIXENT (n=225) achieved ≥4-point reduction in Peak
Pruritus NRS vs 10% with placebo at Week 16 in SOLO 2 (n=221; P<0.001)

POST HOC ANALYSIS

DECREASE IN DAILY PEAK PRURITUS NRS FROM BASELINE OBSERVED IN ADULTS STARTING AS EARLY AS DAY 2 WITH DUPIXENT MONOTHERAPY5

Change in daily Peak Pruritus NRS from baseline in a post hoc analysis of pooled SOLO 1 and
SOLO 2 trials (-4.5% with DUPIXENT [n=457] vs -0.6% with placebo [n=460])

Definitive conclusions cannot be made as this was a post hoc analysis in which data were not multiplicity
controlled and P value was nominal.

aIn the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders.1

bFull analysis set includes all subjects randomized.1

cIn CHRONOS, as needed, subjects received topical calcineurin inhibitors for problem areas only, such as the face, neck, and intertriginous and genital areas.1

dWeek 52 data were limited to patients completing 52 weeks as of the cutoff date.1,2

Explore more Peak Pruritis NRS efficacy results

VIEW ADOLESCENT
(12 TO 17 YEARS) DATA VIEW INFANT TO PRESCHOOLER
(6 MONTHS TO 5 YEARS) DATA VIEW CHILD
(6 TO 11 YEARS) DATA VIEW AD PATIENTS (12+ years)
WITH HAND AND/OR FOOT
INVOLVEMENT DATA

Pruritus NRS assesses the average itch intensity over the previous 24 hours6

It is a patient-reported measure that uses a 0- to 10-point scale, with which patients are asked:

“On a scale of 0 to 10, how would you rate your itch overall (on average) during the previous 24 hours?”

0 - None

1

2

3

4

5

6

7

8

9

10 - The Worst
Imaginable

A reduction of at least 4 points in Peak Pruritus NRS from baseline is a clinically meaningful change.1

READY TO PRESCRIBE DUPIXENT?

DOSAGE AND ADMINISTRATION